GFOR vs. APTO, PMCB, AIM, EVAX, NSTGQ, ZIVO, SNTI, SQZ, PLUR, and COEP
Should you be buying Graf Acquisition Corp IV stock or one of its competitors? The main competitors of Graf Acquisition Corp IV include Aptose Biosciences (APTO), PharmaCyte Biotech (PMCB), AIM ImmunoTech (AIM), Evaxion Biotech A/S (EVAX), NanoString Technologies (NSTGQ), ZIVO Bioscience (ZIVO), Senti Biosciences (SNTI), SQZ Biotechnologies (SQZ), Pluri (PLUR), and Coeptis Therapeutics (COEP). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences (NASDAQ:APTO) and Graf Acquisition Corp IV (NYSE:GFOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
Aptose Biosciences presently has a consensus target price of $19.80, indicating a potential upside of 1,522.95%. Given Graf Acquisition Corp IV's higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than Graf Acquisition Corp IV.
Aptose Biosciences' return on equity of -2.50% beat Graf Acquisition Corp IV's return on equity.
Aptose Biosciences has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Graf Acquisition Corp IV has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Aptose Biosciences received 375 more outperform votes than Graf Acquisition Corp IV when rated by MarketBeat users.
26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 28.5% of Graf Acquisition Corp IV shares are owned by institutional investors. 9.5% of Aptose Biosciences shares are owned by company insiders. Comparatively, 20.0% of Graf Acquisition Corp IV shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Graf Acquisition Corp IV's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.
Summary
Graf Acquisition Corp IV beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.
Get Graf Acquisition Corp IV News Delivered to You Automatically
Sign up to receive the latest news and ratings for GFOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graf Acquisition Corp IV Competitors List
Related Companies and Tools
